Can Takeda Help Deliver Shire's China Rare Disease Dream?

Coming out of the local integration with Baxter's spin-off Baxalta in China, Shire may have to face more uncertainties in the country despite erstwhile acquirer Takeda having a much larger presence there, while competition is also brewing for the merged company from rare disease heavyweights such as Roche and Biogen.

China handshake
WHAT LIES AHEAD FOR THE COMBINED TAKEDA/SHIRE IN CHINA?

Since Takeda Pharmaceutical Co. Ltd. has been pursuing its planned acquisition of Shire PLC in a $62bn deal now agreed by both boards, many have been wondering about how the move - if approved by shareholders - will play out in China, a market where both companies have vowed to grow faster and bigger.

Through the acquisition of Baxter International Inc.'s spin-off business Baxalta Inc. in China, Shire has significantly bolstered its presence there, especially in rare diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia